Amgen Dives Deeper Into Rare Disease Drugs With $27.8 Billion Horizon Deal 0 12.12.2022 18:27 International Business Times Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio amid pressure on its top-selling products and marking the biggest buyout in the sector this year. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
